In the second half of Roger Green's interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups. To Jeff, this trend makes patient advocates a more valuable player in the clinical trial design process, particularly when coupled with the FDA's increasing focus on diversity in trial populations. This will become particularly important because, today, the maj...

Podden och tillhörande omslagsbild på den här sidan tillhör SurfingNASH.com. Innehållet i podden är skapat av SurfingNASH.com och inte av, eller tillsammans med, Poddtoppen.